Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)

Volume 13, 6 Issues, 2015

Download PDF Flyer

Current Neuropharmacology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 113th of 252 in Neuroscience
  • 75th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

T.E. Salt
University College London
Institute of Ophthalmology
London EC1V 9EL

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.049
5 - Year: 3.799

Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

Current Neuropharmacology, 12(3): 239-255.

Author(s): Kris Simone Tranches Dias and Claudio Viegas.

Affiliation: LFQM - Laboratorio de Fitoquimica e Quimica Medicinal, Institute of Chemistry, Federal University of Alfenas, 37130-000, Brazil.


Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable.

The multiple factors involved in AD include amyloid aggregation to form insoluble neurotoxic plaques of Aβ, hyperphosphorylation of tau protein, oxidative stress, calcium imbalance, mitochondrial dysfunction and deterioration of synaptic transmission. These factors together, accentuate changes in the CNS homeostasis, starting a complex process of interconnected physiological damage, leading to cognitive and memory impairment and neuronal death.

A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. This review aims to show some recent advances and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.


Alzheimer’s disease, multi-target directed drugs, neurodegenerative disorders, rational drug design.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
Issue Number: 3
First Page: 239
Last Page: 255
Page Count: 17
DOI: 10.2174/1570159X1203140511153200

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science